Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

646.51$-0.55 -0.08 %
At close       04:00 PM    

Stock Snapshot

647.06
Prev. Close
647.00
Open
69.29B
Market Cap
1.59M
Number of Shares
644.57
Day Low
654.93
Day High
646.51
11.67
P/E Ratio
99.26M
Free Float in %
55.38
EPS 2021
144.07
Book Value per Share
36.49
Cash Flow per Share
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN) stock rallied over -0.08% intraday to trade at $646.51 share on NASDAQ. The stock opened with a fall of % at $647.00 and touched an intraday high of $654.93, rising 1.22% against the last close of $647.06. The stock went to a low of $644.57 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$650.00$650.49$659.76$646.53747,259
2021-09-03$675.62$679.57$686.62$672.0056,460,000
2021-09-02$683.50$675.75$684.90$674.5768,930,000
2021-09-01$674.72$680.96$686.28$671.6382,210,000
2021-08-31$677.51$673.40$681.73$668.3382,950,000
2021-08-30$664.00$677.08$678.69$660.4486,530,000
2021-08-27$668.95$663.29$673.10$660.7542,400,000
2021-08-26$670.06$665.77$674.45$663.2947,330,000
2021-08-25$672.85$669.18$674.00$660.7964,300,000
2021-08-24$665.92$669.95$670.00$656.7373,150,000
2021-08-23$665.21$667.29$671.49$642.6899,260,000
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States

http://www.regeneron.com
914 847 7000
Employees
9123
Sector
Healthcare
Sales or Revenue
12.38B
Industry
Biotechnology
5Y Sales Change
15.70
Fiscal Year Ends
2020-12-30

Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam